MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis
Janneke Anink(Boston Children's Hospital), Dirk Holzinger(University of Duisburg-Essen), Lucy R. Wedderburn(Great Ormond Street Hospital), Thomas Vogl(Goethe University Frankfurt), Dirk Foell(Klinik für Schlafmedizin), Michael Frosch(University Hospital Münster), Gerd Horneff(Asklepios Klinik Sankt Augustin), R. ten Cate(Leiden University), Koert M. Dolman(Reade), Johannes Roth(University of Münster), Faekah Gohar(Boston Children's Hospital), Simona Ursu(Universität Ulm), Femke H. M. Prince(Brigham and Women's Hospital), Marion A. J. van Rossum(Reade), Esther P A H Hoppenreijs(Radboud University Nijmegen), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), M.H. Otten(Erasmus University Rotterdam)
Cited by 81
Related Papers
Activated STING in a Vascular and Pulmonary Syndrome
|New England Journal of Medicine|2014|1.4k
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
|Journal of Clinical Investigation|2018|519
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465